HCA Healthcare, Inc. 8K

HCA Healthcare, Inc. released preliminary Q2 2026 results and reduced its full‑year 2026 earnings guidance due to unfavorable payer mix shifts from health insurance exchanges, partially offset by increased Medicaid supplemental payments.

On July 14, 2026, HCA Healthcare, Inc. announced preliminary, unaudited financial and operating results for the second quarter ended June 30, 2026 and issued revised full‑year 2026 guidance, indicating higher revenues and earnings versus the prior-year quarter but lowering its prior 2026 outlook for net income, Adjusted EBITDA, and diluted EPS. The company reported expected Q2 2026 revenue of approximately $20.23 billion and net income of about $1.699 billion ($7.62 per diluted share), with Adjusted EBITDA of roughly $4.027 billion, while noting volume growth in admissions and ER visits but declines in surgical volumes. Management highlighted a significant unfavorable payer mix shift due to higher uninsured volumes driven by loss of health insurance exchange coverage, estimating a roughly $400 million negative impact on Q2 income before income taxes, partially offset by approximately $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, primarily related to Florida state directed payments. Reflecting these dynamics and updated assumptions for exchange-related payer mix and Medicaid supplemental payments, HCA narrowed and reduced its 2026 guidance ranges to revenues of $77.0–$79.5 billion, net income of $6.3–$6.7 billion, Adjusted EBITDA of $15.4–$16.1 billion, and diluted EPS of $28.70–$30.50, while maintaining planned 2026 capital expenditures of $5.0–$5.5 billion and scheduling its Q2 2026 earnings call for July 24, 2026.

Filing Facts

CIK

860730

Ticker

HCA

Form

8K

Source Type

sec

Accession

0001193125-26-302539

Alert Tier

8